Maria Abbondanza Pantaleo

Curriculum vitae,   Maria Abbondanza Pantaleo, MD

Date and place of birth: August 17, 1973, Scorrano (Le) Italy

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES)

IRCSS Policlinico Sant'Orsola Malpighi, Medical Oncology Unit, Via Massarenti 9, 40138 Bologna

E-mail: maria.pantaleo@unibo.it

Telephone number:   0039 (0)51 6364078   

Fax number: 0039 (0)51 6364037

 

Qualifications and Position:

University Position

- Associate Professor in Medical Oncology since 15/10/2014

 - “Researcher in Medical Oncology” at University of Bologna since 1 March 2006

- Medical Oncologist at Azienda Ospedaliero-Universitaria Polilcinico Sant'Orosla Malpighi, SSD Oncologia Medica Biasco, 1 December 2006

PhD -  “Experimental and clinical Oncology” of Modena and Reggio Emilia University, 2005

Degree at School of  Specialization in Medical Oncology at Bologna University, November 09,  2002 cum summa laude

Degree in Medicine at University of Bologna, October 15, 1998 cum summa laude

Representative of Policlinico Sant'Orsola Malpighi in ERN EURACAN

Responsible of Oncology Research Projetcs of IRCCS Pol. Sant'Orsola

Director of Master in Clinical Study Coordinator

 

Professional Training:

Visiting the  Internal Medicine Unit for 1 year  at Department of Clinical Medicine, Bologna University

Stage at Hematology Unit for 6 months to learn the high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, Bologna University

 

Stage at Oncology Unit for 1 year to learn the clinical and therapy of solid tumors, Bologna University

 

Stage at Laboratory of gastrointestinal histopathology to learn the biology of gastrointestinal carcinomas at Departement of Clinical Medicine and Gastroenterology, Bologna University

 

Course in Cancer Genetics and Pediatric Oncology at Euoropean School of Genetic  Medicine, Genoa

 

Gastrointestinal Oncology Unit, Memorial Sloan-Kettering Cancer Center, New York USA

 

Clinical Immunology Melanoma Unit, Memorial Sloan-Kettering Cancer Center, New York USA

 

Breast Medical Oncology Unit, Memorial Sloan-Kettering Cancer Center, New York USA

 

Grants:

·         Grant for the research project : “Biomolecular prognostic factors of colorectal cancer” at Centro Interdipartimentale di ricerca sul Cancro “Giorgio Prodi”. Funds: “Vanda Vanini” (January-May 2003)

 

·         Grant for the research project : “Novel approach for the screening of colon cancer ” Funds: Ministero dell'Istruzione, dell'Università e della ricerca, FIRB programme at University of Bologna (Aril-December 2003).

 

·         Grant for the research project : “Molecular and morphological characterization of colorectal cancer and related clinical implications” at Centro Interdipartimentale di ricerca sul Cancro “Giorgio Prodi” Funds: Fondazione Cassa di Risparmio di Bologna (CARISBO (January 2004- December 2005)

National and International collaboration:

·       Department of Experimental Diagnostic Imaging, MD Anderson Cancer Center, University of Texas, Houston USA

·       Department of Nuclear Medicine, Hadassah Hospital, Hebrew University Medical School, Jerusalem, Israeli

·       Department of Medicine, Portland VA Medical Center and Oregon Health & Science University Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

·       Istituto Nazionale dei Tumori, Milano

 

Membership:

·         American Society of Clinical Oncology (ASCO)

• American Association of Cancer Research (AACR)
• Associazione Italiana di Oncologia Medica (AIOM)
• European Socitiey of Medical Onoclogy (ESMO)
• Italian Sarcoma Group (ISG)

 

Main research fields:

 

Gastrointestinal stromal tumours (GIST) (www.giststudygroup.it)

 

Visceral Sarcoma (www.sarcomastudyroup.it)

 

Biomolecular prognostic factors of solid tumours and new molecular targets for cancer therapy

 

Molecular Imaging in Medical Oncology

 

 

List of Clinical Trial in GCP :

 

Principal Investigator, Sub-investigator, Co-Investigator

AXAGIST: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy

PROGENSARC: PROfilazione GENomica a scopo terapeutico nei SARComi e molecular tumor board (MTB): studio retrospettivo/prospettico in centri di riferimento

CGT9486-21-301: (PEAK) A Phase 3 Randomized, Open-Label, Multicenter Clinical Study Of Cgt9486+Sunitinib Vs Sunitinib In Subjects With Locally Advanced, Unresectable, Or Metastatic Gastrointestinal Stromal Tumors

EORTC-1553-SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Pfizer A6181036: "A treatment protocol for patients with Gastro-intestinal stromal tumor who are ineligible for participation in other SU011248 protocols and are refractory to or intolerant of Imatinib Mesylate"

               

Pfizer A6181112: "A Phase IIIB, randomized, active controlled open-label study of sunitinib malate (Sutent®) 37.5 mg daily vs imatinib mesylate 800 mg daily in the treatment of patients with Gastrointestinal Stromal Tumors (GIST) who have had progressive disease while on 400 mg daily of imatinib"

 

Pfizer A6181078: "A treatment protocol for patients continuing from a prior SU011248 protocol"

 

EORTC 62024: " Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery"

 

CSTI571B2404 (GOLD reGISTry): "A global observational registry collecting longitudinal data on patients with advanced GIST"

 

CSTI571JDE74: "An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection"

 

CAMN107A2201: "A Randomized, Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib Versus Best Supportive Care With or Without a Tyrosine Kinase Inhibitor (Investigator's Choice) in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Both Imatinib and Sunitinib"

 

CAMN107G2301: "A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib vs. imatinib in adult patients with unresectable or metastatic gastroinestinal stroma tumors (GIST)"

 

CAMN107DDE05: " An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib"

 

EORTC 62063: “A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate”

 

Basket: “Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma”

 

Novartis CAMN107A2409 “An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment”

 

Novartis CSTI571X2103: “A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib”

 

Yondelis: “A non-interventional multicenter, prospective study to evaluate treatment outcome as assessed in routine clinical practice on patients with advanced soft tissue sarcoma treated with trabectedin according to the Summary of Product Characteristics (SmPC)”

ALDOXORUBIN-P3-STS-01 : Studio multicentrico, randomizzato, in aperto, di Fase 3 per valutare l'efficacia e la sicurezza di aldoxorubicina rispetto alla scelta dello sperimentatore in soggetti con sarcomi dei tessuti molli metastatici, localmente avanzati o non resecabili, recidivati o refrattari dopo trattamento chemioterapico non adiuvante

 

Other CV Information

 

• Winner of Best Poster in Sarcoma section at European Society of Medical Oncology (ESMO) Annual Meeting, Milan 2010 Title:1350P CORRELATION OF MICRORNA PROFILE WITH KINASE GENOTYPE IN GASTROINTESTINAL STROMAL TUMOURS (GISTS)
• Teacher at University of Bologna from 2006, Subject Medical Oncology
• Project leader and coordinator of the multidisciplinary group: "giststudygroup", University of Bologna
• Project leader and coordinator of the multidisciplinary group: "sarcomastudygroup", University of Bologna

 

 

Pubblications: Author of more of 200 publications (see Publications section)

Conflict of Interests: Novartis Research Grants; Pfizer speaker fee; Lilly Oncology Speaker fee;Roche Advisory board; Deciphera Advosry Board; Blueprint Medicine Consultant.